Plain-English translation of NCT06389110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing whether (atropine sulfate 0.01%), a medication administered as eye drops, can slow down the progression of nearsightedness in children. Children in the study will receive either the medication or a placebo (inactive drops) once each night for 12 months. Researchers will measure whether the medication helps delay how quickly children's nearsightedness worsens compared to those receiving placebo.
Nearsightedness is becoming increasingly common in children, and it can worsen over time, potentially affecting their vision and quality of life. This trial is testing whether this medication could offer a safe and effective way to slow down that progression, reducing the need for stronger glasses or contact lenses as children grow.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the study medication or placebo drops—neither you nor your doctor will know which one you're getting. You will instill one drop in each eye every night before bed for 12 months. During this time, you will visit the clinic several times so the researchers can measure your eye health, check how your nearsightedness is progressing, and monitor for any side effects. The study will track changes in your prescription strength and the shape of your eye over the year.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Mexico